SCHEMBL274134

SCHEMBL274134

O=C(Nc1ccc(I)cc1C(=O)N/N=C/c1cccc(O)c1)c1cccc(CN2CCC(N3CCCCC3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SLC34A2 O95436 5/20 0.41
SLC34A1 Q06495 1/20 0.40
SLC34A3 Q8N130 1/20 0.40
SLC20A1 Q8WUM9 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
MBTD1 Q05BQ5 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MCHR1 Q99705 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268571 1.00 MEN1 (0.42) MEN1KMT2APOLBTDP1SLC34A2
SCHEMBL267724 0.93 NPC1 (0.44) MEN1KMT2ATDP1SLC34A2SLC34A1
SCHEMBL273682 0.93 NPC1 (0.44) MEN1KMT2ATDP1SLC34A2SLC34A1
SCHEMBL273677 0.93 SLC34A2 (0.49) MEN1KMT2ASLC34A2SLC34A1SLC34A3
SCHEMBL273680 0.93 ACKR3 (0.45) MEN1KMT2ATDP1SLC34A2SLC34A1
SCHEMBL267446 0.93 SLC34A2 (0.49) MEN1KMT2ASLC34A2SLC34A1SLC34A3
SCHEMBL268140 0.93 ACKR3 (0.45) MEN1KMT2ATDP1SLC34A2SLC34A1
SCHEMBL273699 0.92 ACKR3 (0.47) MEN1KMT2APOLBTDP1SLC34A2
SCHEMBL267480 0.92 ACKR3 (0.47) MEN1KMT2APOLBTDP1SLC34A2
SCHEMBL274046 0.92 SLC34A2 (0.49) MEN1KMT2APOLBTDP1SLC34A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MEN1 1638/4885KMT2A 4603/4885POLB 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.